Compare BridgeBio Pharma Inc (BBIO) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Noble Corporation plc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Noble Corporation plc trades at $41.68 (market cap $6.65B). The key difference: BridgeBio Pharma Inc is far larger — about 2.5× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.8% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NE | |
|---|---|---|
Market Cap | $16.46B | $6.65B |
Sector | Health | Technology |
52-Week High | $90.17 | $54.37 |
52-Week Low | $44.81 | $25.70 |
Enterprise Value | $18.02B | $7.90B |
Dividend Yield | — | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Noble Corporation (NE) trades at $41.79, up 4.55% with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $3.29B revenue, 7.17% net margin, and positive cash flow of $228M in 2025. Recent contract wins in Brunei and the UK Continental Shelf worth over $136M demonstrate operational momentum ahead of Q2 2026 earnings on July 27.
Analyst consensus suggests moderate upside with a $50 price target, though mixed earnings history and elevated P/E of 29.15 warrant caution. Key risks include offshore drilling market volatility and execution on new contracts, while institutional sentiment remains divided with 31% buy ratings versus 25% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
